Microbot Medical® Strengthens Its Management Team in Support of the Anticipated Commercial Launch of LIBERTY®
Microbot Medical (Nasdaq: MBOT) has appointed Michal Ahuvia as Director of Operations to support the anticipated commercial launch of its LIBERTY® Endovascular Robotic System in Q2 2025. Ahuvia, who brings over 20 years of operations experience, will focus on ramping up production and improving efficiencies in preparation for commercialization.
Reporting to Simon Sharon, the Company's General Manager and Chief Technology Officer, Ahuvia will be responsible for strengthening manufacturing and operations processes. Her extensive background includes roles at Philips Healthcare, Nanomotion, XACT Robotics, and Jordan Valley, with expertise in process transformation, performance improvement, material planning, production, logistics, and supply chain management.
Microbot Medical (Nasdaq: MBOT) ha nominato Michal Ahuvia come Direttore delle Operazioni per supportare il previsto lancio commerciale del suo LIBERTY® Endovascular Robotic System nel secondo trimestre del 2025. Ahuvia, che porta con sé oltre 20 anni di esperienza nelle operazioni, si concentrerà sull’aumento della produzione e sul miglioramento dell’efficienza in preparazione alla commercializzazione.
Riportando a Simon Sharon, Amministratore Delegato e Chief Technology Officer della Società, Ahuvia sarà responsabile del rafforzamento dei processi di produzione e operativi. Il suo ampio background include ruoli presso Philips Healthcare, Nanomotion, XACT Robotics e Jordan Valley, con competenze nella trasformazione dei processi, nel miglioramento delle performance, nella pianificazione dei materiali, nella produzione, nella logistica e nella gestione della catena di approvvigionamento.
Microbot Medical (Nasdaq: MBOT) ha nombrado a Michal Ahuvia como Directora de Operaciones para apoyar el anticipado lanzamiento comercial de su LIBERTY® Endovascular Robotic System en el segundo trimestre de 2025. Ahuvia, quien cuenta con más de 20 años de experiencia en operaciones, se enfocará en aumentar la producción y mejorar la eficiencia en preparación para la comercialización.
Reportando a Simon Sharon, Director General y Chief Technology Officer de la Compañía, Ahuvia será responsable de fortalecer los procesos de fabricación y operaciones. Su amplia experiencia incluye roles en Philips Healthcare, Nanomotion, XACT Robotics y Jordan Valley, con conocimientos en transformación de procesos, mejora de rendimiento, planificación de materiales, producción, logística y gestión de la cadena de suministro.
Microbot Medical (Nasdaq: MBOT)는 2025년 2분기에 LIBERTY® Endovascular Robotic System의 상업적 출시를 지원하기 위해 Michal Ahuvia를 운영 이사로 임명했습니다. Ahuvia는 20년 이상의 운영 경험을 바탕으로 생산 증가와 효율성 개선에 집중하여 상업화를 준비할 것입니다.
회사의 총괄 관리자이자 최고 기술 책임자인 Simon Sharon에게 보고하는 Ahuvia는 제조 및 운영 프로세스를 강화할 책임이 있습니다. 그녀의 폭넓은 배경에는 Philips Healthcare, Nanomotion, XACT Robotics 및 Jordan Valley에서의 역할이 포함되어 있으며, 프로세스 변환, 성과 개선, 자재 계획, 생산, 물류 및 공급망 관리에 대한 전문 지식을 가지고 있습니다.
Microbot Medical (Nasdaq: MBOT) a nommé Michal Ahuvia au poste de Directrice des Opérations pour soutenir le lancement commercial prévu de son LIBERTY® Endovascular Robotic System au deuxième trimestre de 2025. Ahuvia, qui possède plus de 20 ans d'expérience en opérations, se concentrera sur l'augmentation de la production et l'amélioration de l'efficacité en préparation à la commercialisation.
Relevant de Simon Sharon, Directeur Général et Chief Technology Officer de l'entreprise, Ahuvia sera responsable du renforcement des processus de fabrication et d'opération. Son parcours varié comprend des postes chez Philips Healthcare, Nanomotion, XACT Robotics et Jordan Valley, avec une expertise en transformation des processus, amélioration des performances, planification des matériaux, production, logistique et gestion de la chaîne d'approvisionnement.
Microbot Medical (Nasdaq: MBOT) hat Michal Ahuvia zur Betriebsleiterin ernannt, um den erwarteten Markteintritt ihres LIBERTY® Endovascular Robotic System im 2. Quartal 2025 zu unterstützen. Ahuvia, die über 20 Jahre Erfahrung im Bereich Operations verfügt, wird sich auf die Steigerung der Produktion und die Verbesserung der Effizienz zur Vorbereitung auf die Kommerzialisierung konzentrieren.
Sie berichtet an Simon Sharon, den Geschäftsführer und Chief Technology Officer des Unternehmens, und wird verantwortlich sein für die Stärkung der Herstellungs- und Betriebsprozesse. Ihr umfangreicher Hintergrund umfasst Rollen bei Philips Healthcare, Nanomotion, XACT Robotics und Jordan Valley, mit Expertise in Prozessumwandlung, Leistungsverbesserung, Materialplanung, Produktion, Logistik und Lieferkettenmanagement.
- Planned commercial launch of LIBERTY® system in Q2 2025
- Strategic hire with 20+ years of relevant industry experience
- Strengthening of operational capabilities ahead of product launch
- None.
Insights
The appointment of Ms. Ahuvia as Director of Operations, while a management change, carries strategic importance given the proximity to LIBERTY®'s commercial launch in Q2 2025. Her extensive background in healthcare operations, particularly at Philips Healthcare and XACT Robotics, suggests MBOT is prioritizing manufacturing scalability and cost optimization at a important pre-launch phase.
The endovascular robotics market demands precise production processes and robust supply chain management. With a relatively modest market cap of
For investors, this strategic hire indicates MBOT is transitioning from R&D to commercialization phase, though watch for potential production ramp-up costs impacting near-term margins. The focus on operational efficiency could help optimize the cash burn rate - critical for small-cap medical device companies entering commercialization.
This appointment represents a key pre-commercialization milestone for MBOT's LIBERTY® Endovascular Robotic System. The strategic timing, just months before the planned Q2 2025 launch, suggests confidence in achieving regulatory clearance and market readiness. Ms. Ahuvia's experience with both large medical device companies (Philips) and innovative robotics firms (XACT) brings valuable scaling expertise.
The endovascular robotics market is projected for significant growth, but success requires competitive pricing and reliable supply chains. Her focus on cost reduction and production efficiency could help MBOT achieve favorable unit economics - essential for market penetration against larger competitors. The reporting structure to the CTO indicates a strong focus on maintaining product quality while scaling operations.
Small-cap medical device companies often face challenges in the transition to commercial operations. This hire addresses a critical gap in operational expertise needed for successful market entry, though investors should monitor execution in the coming quarters.
Operations Leader to Enhance Operational Efficiencies by Managing Production Scale-up and Cost Reduction Activities to Support Commercialization
BRAINTREE, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, today announced the appointment of Ms. Michal Ahuvia, to the newly created role of Director of Operations. In this role, Ms. Ahuvia will assume responsibility to ramp-up production and improve production efficiencies as the Company prepares for the planned commercial launch of LIBERTY®, which is anticipated in the second quarter of 2025. Ms. Ahuvia will report to Simon Sharon, the Company’s General Manager and Chief Technology Officer, and her addition is expected to play a crucial role in strengthening the Company’s manufacturing and operations processes.
Ms. Ahuvia brings over 20 years of experience in operations with track records in process transformation, performance improvement, material planning, production, logistics, and supply chain management. Prior to joining Microbot Medical, Ms. Ahuvia held operational and supply chain positions at Philips Healthcare, Nanomotion, XACT Robotics and Jordan Valley. Michal holds a B.Sc. in Industrial Engineering and Management from Ben-Gurion University.
“Ramping production of LIBERTY® in the most efficient way is a critical activity and key part of our commercial strategy and future success,” commented Harel Gadot, Chairman, CEO and President. “Michal brings a wealth of knowledge and experience, and I’m confident that her experience will help execute our operational plans and meet our commercial objectives.”
About Microbot Medical®
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems.
Further information about Microbot Medical® is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, the Company’s need for and ability to obtain additional working capital and expertise to continue its transition to a commercially focused company, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic System, uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will grant 510(k) clearance to commercially market the LIBERTY® Endovascular Robotic System in the United States, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact: IR@microbotmedical.com
FAQ
When is Microbot Medical (MBOT) planning to launch the LIBERTY® Endovascular Robotic System?
Who did Microbot Medical (MBOT) appoint as Director of Operations in January 2025?
What are the main responsibilities of MBOT's new Director of Operations?
What is Michal Ahuvia's professional background before joining MBOT?
